Chronic subcutaneous infusion of ouabain causes hypertension via central pathways involving angiotensin type 1 (AT1) receptor stimulation. The present study assessed plasma and tissue ANG I and II levels as well as AT1 receptor and angiotensin-converting enzyme (ACE) mRNA levels and binding densities by real-time PCR and in vitro autoradiography in relevant brain nuclei and peripheral tissues (heart and kidney) in rats at 1 and/or 2 wk after start of ouabain infusion at 50 g/day. After 2 wk (but not after 1 wk), blood pressures significantly increased (ϩ15 mmHg). At 2 wk, plasma ANG I and II levels were markedly suppressed by ouabain. In contrast, in the heart and kidneys, ANG I levels were not affected, and ANG II levels tended to decrease, whereas in the hypothalamus ANG II content clearly increased. At 1 wk, no changes in ACE and AT1 receptor densities were seen. After 2 wk, there were significant decreases in AT1 receptor mRNA and densities in the organum vasculosum of the lamina terminalis (OVLT), subfornical organ (SFO), and paraventricular nucleus (PVN). ACE densities decreased only in the OVLT and SFO, but ACE mRNA showed more variable responses (decrease in OVLT vs. increase in PVN). In the kidneys, at 2 wk both AT1 receptor and ACE densities were decreased, but mRNA abundance did not change. The heart showed no significant changes. The increase in hypothalamic ANG II content and associated decreases in central AT1 receptor and ACE densities support the involvement of the brain renin-angiotensin system in the central hypertensive mechanism of action of ouabain.
CHRONIC SUBCUTANEOUS infusion of ouabain results in hypertension in normotensive rats with accumulation of ouabain in the hypothalamus and adrenals (8, 12 ). Ouabain appears to cause hypertension via central sympathoexcitatory mechanisms because concurrent central infusion of antibody Fab fragments that bind ouabain and related steroids with high affinity prevents the development of hypertension (8) , and ganglionic blockade reverses the hypertension (12) . Furthermore, excitotoxic lesions of the most ventral part of the anteroventral third ventricle region of the hypothalamus prevent the ouabaininduced hypertension (25) .
Intracerebroventricular infusion of losartan, an angiotensin type 1 (AT 1 ) receptor blocker, concomitantly with subcutaneous infusion of ouabain for 2 wk also prevents the ouabaininduced hypertension, demonstrating that ouabain causes hypertension via central pathways in which the renin-angiotensin system (RAS) plays an essential role (7) . Ouabain may decrease renal renin release (10) and does not activate the circulatory RAS (12, 23) . Effects of ouabain on the brain RAS have not yet been studied. Ouabain may increase the activity of the brain RAS through increased ANG II release and/or may increase other components of the RAS, such as angiotensinconverting enzyme (ACE) or AT 1 receptor densities.
The objective of the present study was to assess the effects of chronic subcutaneous infusion of ouabain on components of the brain RAS relative to changes in peripheral tissue RAS and the circulatory RAS. AT 1 receptor and ACE mRNA levels and binding densities were assessed in relevant brain nuclei and as peripheral tissues in the heart and kidney. Brain nuclei that express components of the RAS and regulate cardiovascular homeostasis were examined. These brain nuclei include circumventricular organs (CVOs) such as the organum vasculosum of the lamina terminalis (OVLT) and subfornical organ (SFO), which lie outside the blood-brain barrier (BBB), as well as nuclei within the BBB, such as the paraventricular nucleus (PVN) and median preoptic nucleus (MnPO) (2) . ANG I and II contents were measured in the hypothalamus, heart, and kidneys, and the activity of the circulatory RAS was assessed by measurements of plasma renin activity (PRA) and plasma ANG I and II concentrations.
MATERIALS AND METHODS

Animals
Male Wistar rats (Charles River, Montreal, Canada) weighing 150 -200 g were housed on a 12:12-h light-dark cycle at 24°C, fed regular rodent chow, and allowed tap water ad libitum for 5 days to acclimatize before entering the study. All experimental procedures were carried out in accordance with the guidelines of the Canadian Council on Animal Care and approved by the University of Ottawa Animal Care Committee for the use and care of laboratory animals.
Treatment
Rats received a chronic subcutaneous infusion of either 0.9% saline or 50 g of ouabain/day via osmotic minipump for 1 wk (2 experiments) or for 2 wk (4 experiments). Ouabain infused subcutaneously at a dose of 50 g/day causes mild hypertension in Wistar rats (26) . An osmotic minipump (model 2002, Alza, Palo Alto, CA), with an infusion rate of 12 l/day and filled with either saline or ouabain dissolved in saline (4.17 mg/ml), was implanted subcutaneously on the back of the rat under halothane-oxygen anesthesia. First, after both 1 and 2 wk of infusion, two separate experiments were performed, one for measurement of blood pressure and one for binding densities to exclude beguiling influences of surgical stress on brain AT1 receptor and ACE densities. Subsequently, at 2 wk, two additional experiments were done, one for measurement of plasma and tissue angiotensins and one for mRNA measurements.
Blood Pressure
Resting blood pressure was determined as described previously (26) . Briefly, at the end of the treatment period, while the animals were under halothane-oxygen anesthesia, a polyethylene catheter (PE-50) was inserted into the left carotid artery, tunneled subcutaneously to the nape, and secured to the skin. After a 17-h recovery period, mean arterial pressure and heart rate were recorded in conscious, unrestrained animals. In one 2-wk experiment, an arterial blood sample was then obtained, and the heart, kidneys, and brain were rapidly excised as previously described (11) .
Quantitative In Vitro AT 1 Receptor and ACE Autoradiography
Rats were killed by decapitation, and the brains, hearts, and kidneys were removed and quickly frozen in 2-methylbutane at Ϫ40°C and stored at Ϫ80°C. Standard autoradiography for quantitative analysis of ACE and AT 1 receptor binding was carried out as described previously (27) . To investigate AT1 receptor binding, 20-m sections were preincubated in 10 mM sodium phosphate buffer, pH 7.4, containing 5 mM Na 2EDTA (15) . Quantification was done by using a computer-assisted image analysis system, AIS/C (Imaging Research, St. Catharines, Ontario, Canada), and conversion (to fmol/mg and fmol/g wet weight of tissue, respectively) was done by comparing them with the calibrated relative optical density of the 125 I-standards.
RT-PCR
RNA isolation and reverse transcription reaction. Rats were perfused with chilled diethyl pyrocarbonate-treated PBS (pH 7.4) under pentobarbital sodium anesthesia. The brains, hearts and kidneys were removed, immediately frozen in isopentane, and placed on dry ice and then stored at Ϫ80°C until use. Renal cortex and medulla as well as the left ventricle (LV) and right ventricle (RV) of the heart were homogenized in TRIzol Reagent buffer (Invitrogen, Burlington, ON, Canada) by using a Polytron. Serial 80-m-thick coronal brain slices were cryosectioned, and specific nuclei (OVLT, MnPO, SFO, and PVN) (15) were punched out by using prechilled 25-l Drummond Microdispensers (Drummond Scientific). The tissue pellet was homogenized in 0.2 ml TRIzol Reagent by using a pestle (Bel-ArtProducts, Pequannock, NJ) driven by a Pellet Pestle Motor, and another 0.3 ml TRIzol was added thereafter. Total RNA was isolated from tissues according to the manufacturer's instructions. To eliminate potential genomic DNA contamination, samples were treated with DNase I (Ambion, Austin, TX) before reverse transcription reaction. cDNA was synthesized using Superscript II RNase HReverse Transcriptase (Invitrogen) at 42°C for 50 min.
Real-time PCR. Real-time PCR amplifications were performed with a Roche Light Cycler by using Fast Start DNA Master SYBR Green I (Roche Diagnostics, Penzberg, Germany). Two microliters of the RT product from each sample was used as a template. The specific AT1 receptor, ACE, and phosphoglycerate kinase (PGK) primer sequences used are listed in Table 1 . The real-time PCR conditions were as follows: an initial step of 95°C for 10 min followed by 40 cycles of denaturation at 95°C for 5 s, and annealing of primers to the target for 5 s at 60°C for the AT1 receptor primers, or 62°C for the ACE and PGK primers. The extension step was performed at 72°C, and the extension time was determined by the formula: amplicon length/25 s. Real-time PCR efficiencies (E) for AT1 receptor, ACE, and PGK amplification were 1.96, 1.84, and 1.88, respectively, and were calculated according to the equation: E ϭ 10 Ϫ1/slope . The specificity of real-time PCR products was documented with a melting curve analysis. In addition, high-resolution gel electrophoresis was performed to confirm the amplification of a single product of the appropriate size for each gene (Table 1) . Real-time RT-PCR analysis was performed in duplicate.
Serial 10-fold dilutions of RT product (initially 5 g of RNA) were used to generate relative external standards for each gene. Expression was normalized with PGK levels as an endogenous reference, dividing the amount of the target gene by the PGK quantity.
ANG I and II and Ouabain Assays
Procedures for the sample collection, processing of samples, as well as the actual assays have been described in detail (9, 11, 17) . Plasma and tissue angiotensins were assessed by radioimmunoassay (RIA) after separation on HPLC. PRA was determined by RIA for ANG I, generated by incubation of plasma for 30 min at 37°C and pH 7.5. Plasma ouabain levels were measured by ELISA.
Statistical Analysis
Data represent means Ϯ SE. Differences between groups were compared by unpaired t-test. The level of statistical significance was set at P Ͻ 0.05. 
RESULTS
Mean Arterial Pressure, Heart Rate, and Plasma Ouabain Levels
Chronic subcutaneous infusion of ouabain over 2 wk significantly increased resting mean arterial pressure (118 Ϯ 2 vs. 103 Ϯ 2 mmHg, P Ͻ 0.05 in one experiment, and 121 Ϯ 2 vs. 104 Ϯ 3 mmHg, P Ͻ 0.05 in the second experiment) but not yet significantly after 1 wk (116 Ϯ 3 vs. 109 Ϯ 4 mmHg) compared with controls. Resting heart rate showed minor increases by 10 -40 beats/min (significant in one 2-wk experiment). Body weights did not differ between ouabain-vs. vehicle-treated animals. After 2-wk infusion of ouabain, plasma ouabain levels were 8.7 Ϯ 1.1 ng/ml compared with 2.1 Ϯ 0.4 ng/ml (P Ͻ 0.001) in control rats, the latter reflecting endogenous "ouabain."
AT 1 Receptor and ACE Densities
Brain. Representative autoradiographs for AT 1 receptor and ACE binding densities in the OVLT and PVN are shown in Fig. 1 . Subcutaneous ouabain infusion for 1 wk caused small, nonsignificant decreases in AT 1 receptor densities in the brain areas studied (Fig. 2A) . After 2 wk of ouabain treatment, AT 1 receptor densities had significantly decreased in the OVLT, SFO, and PVN (by 14 -18%) and not significantly in the MnPO (Fig. 2B) . Ouabain infused subcutaneously for 1 wk had no effect on ACE densities in the brain areas studied (Fig. 3A) . However, ACE densities were decreased after 2 wk of ouabain treatment but only significantly in brain nuclei outside the BBB (Fig. 3B) . ACE densities decreased by 48% in the OVLT and by 26% in the SFO vs. 14% (not significant) in the PVN.
Kidney and heart. In the kidney, AT 1 receptor binding is localized to the cortex and medulla, while ACE binding is present in the proximal convoluted tubule. Subcutaneous infusion of ouabain for 1 wk caused small, nonsignificant decreases in renal AT 1 receptor and ACE densities (Fig. 4) . In contrast, both AT 1 receptor and ACE densities decreased significantly after 2 wk of ouabain treatment (Fig. 4) . AT 1 receptor densities decreased by 34% in the cortex and by 29% in the medulla, whereas ACE densities in the proximal convoluted tubule decreased by 14%.
In contrast to the brain and the kidney, subcutaneous infusion of ouabain caused only small, nonsignificant decreases in AT 1 receptor or ACE densities in the LV of the heart (Fig. 4) .
AT 1 Receptor and ACE mRNA Levels
Brain. Subcutaneous infusion of ouabain for 2 wk caused significant decreases in AT 1 receptor mRNA levels in the OVLT and PVN (by ϳ50%) compared with the control group and tended (NS) to decrease levels in the MnPO and SFO (Fig.  5A ). ACE mRNA levels were significantly decreased by 15% in the OVLT but increased by 90% in the PVN after 2-wk subcutaneous infusion of ouabain (Fig. 5B) . The MnPO and SFO showed minor nonsignificant increases in ACE mRNA abundance (Fig. 5B) .
Kidney. Infusion of ouabain for 2 wk caused only minor (NS) changes in AT 1 receptor and ACE mRNA abundance in both the cortex and the medulla (data not shown). 
Circulating and Tissue ANG I and II Levels
In the plasma, all three components of the RAS, i.e., PRA, ANG I, and II levels, were markedly decreased after infusion of ouabain for 2 wk (Table 2 ). In the LV and kidney, ANG I and II levels showed either no changes or tended to decrease (significant only for ANG I in the renal medulla). In contrast, in the hypothalamus, ANG I levels did not change, but ANG II levels increased severalfold (Table 2) .
DISCUSSION
The present study demonstrates that the development of ouabain-induced hypertension is associated with a different pattern of changes in the brain vs. the renal and circulatory RAS. In the hypothalamus, ANG II levels clearly increased, whereas AT 1 receptors showed decreases in both densities and mRNA, and ACE showed variable responses. In contrast, in the kidneys, ANG I and II levels tended to decrease, whereas both ACE and AT 1 receptors showed clear decreases in binding densities but no change in mRNA abundance. The circulatory RAS, i.e., PRA and plasma ANG I and II levels, showed a marked suppression.
Brain RAS
Ouabain for 2 wk increased hypothalamic ANG II levels severalfold with no change in ANG I levels. Because plasma renin, ANG I, and ANG II levels markedly decreased, it is likely that these increased ANG II levels in the hypothalamus reflect locally produced ANG II. The higher hypothalamic ANG II levels likely do not only reflect increased ANG II stores but also increased release of ANG II from nerve terminals because the ouabain-induced hypertension depends on AT 1 receptor stimulation in the central nervous system (CNS) (7). These higher ANG II levels were associated with significant decreases in AT 1 receptor densities in several nuclei. Autoradiography assesses the number of receptors on the plasma membrane. Several in vitro studies demonstrated that ANG II causes a reduction of AT 1 receptor numbers at the cell surface (16, 24) . Considering that ouabain can increase local release of ANG II by increasing ANG II release from nerve terminals (18) , it appears reasonable to conclude that an increase in local ANG II release by ouabain leads to enhanced internalization of the ligand-receptor complex and thereby less AT 1 receptors at the cell surface. More chronically, an actual decrease in production of receptors by ANG II also may contribute (1) . In the present study, after 2 wk of ouabain both mRNA and densities for AT 1 receptors were largely in parallel found decreased in the brain nuclei studied. This decrease in AT 1 receptors production may compensate for enhanced ANG II release, if AT 1 receptor numbers on the neuronal membrane are rate limiting, i.e., not present in excess relative to the local ANG II levels. If so, this likely only in part offsets the impact of higher ANG II release because the chronic sympathoexcitatory and pressor responses to ouabain are mediated through central AT 1 receptors stimulation (7) .
ACE densities in the brain decreased as well, but interestingly only clearly in the two nuclei outside the BBB (i.e., the OVLT and the SFO), and little in the two nuclei inside the BBB (i.e., PVN and MnPO). ACE mRNA abundance showed a small decrease in the OVLT, minor increases in MnPO and SFO, and a marked increase in the PVN. The CVOs, OVLT and SFO, do not express angiotensinogen (4) and respond to circulating ANG II. Ouabain markedly decreased plasma ANG II levels and presumably therefore also the levels in these two CVOs. It is not known whether ACE in these areas responds to 
Comparison with Responses to Endogenous "Ouabain"
The responses of ACE and AT 1 receptors in the hypothalamus to the endogenous equivalent of ouabain, i.e., "ouabain" or ouabain-like compound, show a distinctly different pattern. In rats with congestive heart failure after myocardial infarction, AT 1 receptor and ACE densities show clear increases in the SFO, OVLT, MnPO, and PVN, and most of the increases are secondary to "ouabain" in the CNS because central infusions of Fab fragments binding endogenous "ouabain" prevent the increases (22) . Similarly, we reported that in Dahl salt-sensitive rats on high salt intake, ACE mRNA and enzymatic activity markedly increase in the hypothalamus, which could be fully prevented by blockade of central "ouabain" by Fab fragments (29) . Several factors may contribute to this apparent discrepancy between effects of exogenous ouabain and endogenous "ouabain" on regulation of ACE and AT 1 receptors in the hypothalamus. The most important difference may be that systemic infusion of ouabain will likely result in a global distribution of ouabain across the CNS and therefore exert global effects, whereas the release and action of endogenous "ouabain" is likely more localized, e.g., in the MnPO (3), and therefore causes specific, localized effects. Downstream, such nucleus specific effects may cause opposite regulation of ACE and AT 1 receptors than the global effects of exogenous ouabain, which are also confounded potentially by the peripheral effects of subcutaneously infused ouabain.
Circulatory and Renal RAS
Plasma renin and plasma ANG I and II levels were markedly suppressed by chronic infusion of ouabain. This finding is consistent with previous studies showing decreases in renin release from the kidneys by ouabain both in vitro (13) and in vivo after acute intrarenal infusion (10) . Other studies did not report changes in PRA (12) and plasma ANG II levels (23), perhaps reflecting the lower rates of infusion in these studies. ANG I and II levels in the heart and kidneys showed more limited responses to ouabain with modest decreases mainly in the renal medulla. This differential pattern of changes compared with the circulatory RAS likely reflects the active regulation of the tissue ANG I and II levels in these two organs (11, 30) . On the other hand, the kidneys showed significant decreases in ACE and AT 1 receptor densities without a change in mRNA abundance. Increases in ANG II levels by chronic infusion decrease renal AT 1 receptor densities (6, 20) without downregulation of mRNA or protein levels (5, 20) , consistent with posttranscriptional regulation by, e.g., increased receptor internalization after binding of ANG II to its receptor (24) . It appears unlikely, therefore, that a decrease in renal ANG II levels, as caused by ouabain, would have caused the decrease in renal densities. However, the ANG II levels measured reflect tissue steady-state levels, and one cannot exclude that these were decreased because of higher local release by ouabain (14, 21) . Besides renin and ANG II release, ouabain affects several other mechanisms, such as endothelin (28) , aldosterone (21), or renal sympathetic activity (7, 8) , which may change AT 1 receptor densities. In the kidneys, ouabain also decreased ACE densities without a concomitant change in mRNA abundance. ACE is generally considered to be downregulated by ANG II (19) . However, in the kidneys, chronic infusion of ANG II caused a clear (35%) increase in ACE binding densities in the proximal convoluted tubules (6) , in contrast to the decrease in AT 1 receptor densities (6) . In this study (6) , ACE mRNA was not measured. If ouabain indeed lowered intrarenal renin release and ANG I and II formation, lower ANG II levels may therefore have decreased ACE binding densities through posttranscriptional regulation because mRNA abundance did not change. However, we measured mRNA levels in the whole cortex and medulla and, e.g., in situ hybridization is needed to assess whether local changes occurred in proximal convoluted tubules.
In conclusion, the present study indicates that chronic subcutaneous infusion of ouabain at 50 g/day is associated in the CNS with a severalfold increase in ANG II content in the hypothalamus and decreases in AT 1 receptor and ACE densities in nuclei involved in cardiovascular control. In contrast, the circulatory and renal RAS were suppressed. Together with previous functional studies showing that sympathoexcitatory and pressor responses to ouabain are mediated through AT 1 receptor stimulation in the CNS, these studies suggest that ouabain specifically activates the brain RAS.
